EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance–Associated Mutations or M184I/V in Proviral DNA

Tracy L Diamond iD, Anjana Grandhi, Monica Fuszard iD, Yayun Xu, Uchechukwu Nwoke, Ying Zhang, Stephanie O Klopfer iD, Karen Eves iD, Jaime Benner, Mengchun Li iD, Wayne Greaves, Rima Lahoulou und 3 weitere

The Journal of Infectious Diseases · 2026

DOI: 10.1093/infdis/jiag257 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Tracy L Diamond und 14 weiteren Autor:innen. Beteiligte Einrichtung: MRL, Merck & Co., Inc., Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: Anti-HIV Agents, Drug Resistance, Viral, HIV Infections, HIV-1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC, Merck & Co., Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Doravirine/islatravir (DOR/ISL) is a 2-drug, single-tablet regimen in clinical development for once-daily treatment of adults living with HIV-1. We examined the impact of baseline resistance-associated mutations (RAMs) in proviral DNA on the response to DOR/ISL (100/0.25 mg) in virologically suppressed participants in three phase 3 studies.

Methods

Samples were collected pre-dose from participants in studies P051 (NCT05631093), P052 (NCT05630755), and P054 (NCT05766501) to evaluate RAMs in proviral DNA at baseline. The prevalence of baseline non-nucleoside reverse transcriptase inhibitor (NNRTI) RAMs and M184I/V, and their impact on virologic suppression (HIV-1 RNA <50 copies/mL) at week 48, as well as on types of viremia (confirmed HIV-1 RNA ≥200 copies/mL, low-level viremia, and transient viremia), was examined. Samples from participants with confirmed HIV-1 RNA ≥200 copies/mL or who discontinued from treatment with HIV-1 RNA ≥200 copies/mL were assessed for viral drug resistance.

Results

Among 1227 participants who switched to DOR/ISL, 323 (26.3%) had baseline NNRTI RAMs and 70 (5.7%) had baseline M184I/V. At week 48, DOR/ISL maintained HIV-1 RNA <50 copies/mL in ≥88% of participants with and/or without NNRTI RAMs and/or M184I/V detected in proviral DNA at baseline. The percentage of participants in each viremia category was comparable with regard to the presence or absence of NNRTI RAMs and/or M184I/V. No treatment-emergent resistance to DOR or ISL was observed in the 7 participants who met criteria for postbaseline resistance testing.

Conclusions

Baseline NNRTI RAMs and M184I/V in proviral DNA did not impact virologic outcomes through 48 weeks after switching to DOR/ISL (100/0.25 mg). Clinical Trials Registration ClinicalTrials.gov: NCT05631093, NCT05630755, NCT05766501.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsDrug Resistance, ViralHIV InfectionsHIV-1ProvirusesReverse Transcriptase InhibitorsAdultFemaleHumansMaleMiddle AgedDNA, ViralDrug CombinationsMutationPyridonesTriazolesViral LoadDeoxyadenosines

Stichwörter der Autor:innen

HIV-1oralresistance analysistreatmentvirologically suppressed

Substanzen

Anti-HIV AgentsDNA, Viraldoravirine, islatravir drug combinationDrug CombinationsPyridonesReverse Transcriptase InhibitorsTriazolesDeoxyadenosines

Autor:innen und Institutionen

  • MRL, Merck & Co., Inc., Rahway, New Jersey, USA.

ORCID-Profile: Tracy L Diamond, Monica Fuszard, Stephanie O Klopfer, Karen Eves, Mengchun Li

Förderung

  • Merck Sharp & Dohme LLC
  • Merck & Co., Inc.

Zitieren

APA

Diamond, T. L., Grandhi, A., Fuszard, M., Xu, Y., Nwoke, U., Zhang, Y., Klopfer, S. O., Eves, K., Benner, J., Li, M., Greaves, W., Lahoulou, R., Kim, J., Fox, M. C., & Asante-Appiah, E. (2026). Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance–Associated Mutations or M184I/V in Proviral DNA. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag257

Vancouver

Diamond TL, Grandhi A, Fuszard M, Xu Y, Nwoke U, Zhang Y, et al. Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance–Associated Mutations or M184I/V in Proviral DNA. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag257

BibTeX
@article{Diamond2026,
  author = {Diamond, Tracy L and Grandhi, Anjana and Fuszard, Monica and Xu, Yayun and Nwoke, Uchechukwu and Zhang, Ying and Klopfer, Stephanie O and Eves, Karen and Benner, Jaime and Li, Mengchun and Greaves, Wayne and Lahoulou, Rima and Kim, Jason and Fox, Michelle C and Asante-Appiah, Ernest},
  title = {Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance–Associated Mutations or M184I/V in Proviral DNA},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiag257}
}
Kostenlos starten →